专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08173651B2 Pyridine compounds 有权
标题翻译：吡啶化合物
公开(公告)号：US08173651B2
公开(公告)日：2012-05-08
申请号：US12722066
申请日：2010-03-11
申请人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Teresa Przewloka , Hao Li , Howard P. Ng , Zachary Demko
发明人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Teresa Przewloka , Hao Li , Howard P. Ng , Zachary Demko
IPC分类号： A61K31/5377
CPC分类号： C07D413/12 , C04B35/632 , C07D213/77 , C07D401/12 , C07D405/12
摘要： This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.
摘要翻译：本发明的特征在于式（I）化合物：化合物的药物组合物，以及使用该化合物治疗特别是IL-12相关疾病和病症的方法。

2. 发明申请

US20110250191A1 COMPOSITION FOR ENHANCING PHYSICAL PERFORMANCE 有权
标题翻译：用于增强身体健康的组合物
公开(公告)号：US20110250191A1
公开(公告)日：2011-10-13
申请号：US12901991
申请日：2010-10-11
申请人： Thomas Christian Lines , Mitsunori Ono
发明人： Thomas Christian Lines , Mitsunori Ono
IPC分类号： A61K38/43 , A61K31/525 , A61K31/675 , A61P39/00 , A61P39/06
CPC分类号： A61K31/352 , A23L2/02 , A23L33/105 , A23L33/15 , A23V2002/00 , A61K31/185 , A61K31/353 , A61K31/355 , A61K31/375 , A61K31/4415 , A61K31/445 , A61K31/455 , A61K31/51 , A61K31/522 , A61K31/525 , A61K31/675 , A61K31/7048 , A61K31/714 , A61K36/16 , A61K36/185 , A61K36/48 , A61K45/06 , A61K2300/00 , A23V2250/214 , A23V2250/2116 , A23V2250/2108 , A23V2250/7042 , A23V2250/7044 , A23V2250/7046 , A23V2250/704 , A23V2250/7052 , A23V2250/706 , A23V2250/712 , A23V2250/70 , A23V2200/322 , A23V2250/21168 , A23V2200/33 , A23V2200/30
摘要： This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.
摘要翻译：本发明涉及含有槲皮素，维生素B1，维生素B2，维生素B3，维生素B6，维生素B12，维生素C，咖啡因，表没食子儿茶素没食子酸酯，表儿茶素，表儿茶素没食子酸酯和表没食子儿茶素的组合物。

3. 发明授权

US07935698B2 Heteroaryl-hydrazone compounds 有权
标题翻译：杂芳基腙化合物
公开(公告)号：US07935698B2
公开(公告)日：2011-05-03
申请号：US10985716
申请日：2004-11-10
申请人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Elena Kostik , Howard P. Ng
发明人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Elena Kostik , Howard P. Ng
IPC分类号： A61K31/535 , C07D413/14
CPC分类号： C07D213/74 , C07D239/47 , C07D251/16 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12
摘要： This invention relates to compounds having a formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, hydrate, prodrug or polymorph thereof wherein X is —C(Rg)═N-A. The invention also relates to methods of treating IL-12 overproduction-related disorders, methods of treating or preventing disorders related with excessive bone loss, methods for inhibiting osteoclast formation, and methods for treating or preventing a disorder associated with excessive bone resorption.
摘要翻译：本发明涉及具有式（I）的化合物或其药学上可接受的盐，溶剂合物，包合物，水合物，前药或多晶型物，其中X为-C（R g）= N-A。本发明还涉及治疗IL-12过度生产相关疾病的方法，治疗或预防与过度骨丢失相关的障碍的方法，用于抑制破骨细胞形成的方法，以及用于治疗或预防与过度骨吸收相关的病症的方法。

4. 发明申请

US20100280075A1 PACLITAXEL ENHANCER COMPOUNDS 审中-公开
标题翻译： PACLITAXEL增强化合物
公开(公告)号：US20100280075A1
公开(公告)日：2010-11-04
申请号：US12692895
申请日：2010-01-25
申请人： Keizo Koya , Lijun Sun , Shoujun Chen , Noriaki Tatsuta , Yaming Wu , Mitsunori Ono
发明人： Keizo Koya , Lijun Sun , Shoujun Chen , Noriaki Tatsuta , Yaming Wu , Mitsunori Ono
IPC分类号： A61K31/444 , A61K31/422 , A61K31/4045 , A61K31/381 , A61K31/337 , A61K31/341 , A61P35/00
CPC分类号： A61K47/48176 , A61K31/16 , A61K31/165 , A61K31/277 , A61K31/337 , A61K31/381 , A61K31/44 , A61K31/505 , A61K31/53 , A61K47/58 , C07C327/56 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D209/42 , C07D209/44 , C07D213/83 , C07D261/18 , C07D305/14 , C07D307/68 , C07D333/38 , C07D333/68 , C07D407/12
摘要： Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—.R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.R7 and Rg are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and Rg is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group.Z is ═O or ═S.Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent.Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with Paclitaxel or an analog of Paclitaxel.
摘要翻译：公开了由结构式（I）表示的化合物：Y是共价键，亚苯基或取代或未取代的直链烃基。此外，Y与它所键合的两个> C = Z基团一起是取代或未取代的芳族基团。优选Y为共价键或-C（R 7 R 8） - 。 R 1和R 2独立地是芳基或取代的芳基，R 3和R 4独立地是-H，脂族基团，取代的脂族基团，芳基或取代的芳基。 R5-R6独立地是-H，脂族基团，取代的脂族基团，芳基或取代的芳基。 R7和Rg各自独立地为-H，脂族或取代的脂族基团，或R7为-H，Rg为取代或未取代的芳基，或者R7和R8一起为C2-C6取代或未取代的亚烷基。 Z为═O或═S。还公开了包含本发明化合物和药学上可接受的载体或稀释剂的药物组合物。还公开了通过向受试者施用结合式（I）的化合物与紫杉醇或紫杉醇的类似物组合来治疗患有癌症的受试者的方法。

5. 发明申请

US20100173413A1 PYRIDINE COMPOUNDS 有权
标题翻译：吡啶化合物
公开(公告)号：US20100173413A1
公开(公告)日：2010-07-08
申请号：US12722066
申请日：2010-03-11
申请人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Teresa Przewloka , Hao Li , Howard P. Ng , Zachary Demko
发明人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Teresa Przewloka , Hao Li , Howard P. Ng , Zachary Demko
IPC分类号： C12N5/02 , A61K31/5377 , A61P37/06 , A61P29/00 , A61P1/04 , A61P17/00 , A61P19/10 , A61P19/02 , A61P19/00 , A61P35/04
CPC分类号： C07D413/12 , C04B35/632 , C07D213/77 , C07D401/12 , C07D405/12
摘要： This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.
摘要翻译：本发明的特征在于式（I）化合物：化合物的药物组合物，以及使用该化合物治疗特别是IL-12相关疾病和病症的方法。

6. 发明申请

US20090092735A1 METHOD FOR PREPARING STABLE HOP POWDER 审中-公开
标题翻译：制备稳定蜂巢粉的方法
公开(公告)号：US20090092735A1
公开(公告)日：2009-04-09
申请号：US11868226
申请日：2007-10-05
申请人： Naoto Yamaguchi , Mitsunori Ono
发明人： Naoto Yamaguchi , Mitsunori Ono
IPC分类号： C12C3/00 , C12C3/02
CPC分类号： C12C3/06
摘要： This invention features a method of making hop powder containing stable alkaline salts of hop bitter acids and an edible carrier. Also within the scope of this invention is a hop product containing alkaline salts of hop bitter acids and an edible carrier.
摘要翻译：本发明的特征在于制备含有稳定的苦酸碱性盐和可食用载体的啤酒花粉的方法。也包括本发明范围内的啤酒花产品，其含有啤酒花苦酸的碱性盐和可食用的载体。

7. 发明申请

US20090005594A1 Synthesis of taxol enhancers 失效
标题翻译：紫杉醇增强剂的合成
公开(公告)号：US20090005594A1
公开(公告)日：2009-01-01
申请号：US12231217
申请日：2008-08-29
申请人： Shoujun Chen , Lijun Sun , Zhi-Qiang Xia , Keizo Kova , Mitsunori Ono
发明人： Shoujun Chen , Lijun Sun , Zhi-Qiang Xia , Keizo Kova , Mitsunori Ono
IPC分类号： C07C327/00
CPC分类号： C07D213/77 , C07C327/56 , C07C2601/14 , C07D209/42 , C07D209/44 , C07D213/83 , C07D261/18 , C07D307/54 , C07D333/38 , Y02P20/55
摘要： Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I): The thiohydrazide product compound is represented by Structural Formula (II): In Structural Formulas (I)-(II), R1 and R2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R2 is an aryl group or a substituted aryl group, then R5 is a hydrazine protecting group; and when R2 is an aliphatic or substituted aliphatic group, then R5 is —H or a hydrazine protecting group. R10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.
摘要翻译：公开了从酰肼起始化合物制备硫代酰肼产物化合物的方法。酰肼起始化合物由结构式（I）表示：硫代酰肼产物化合物由结构式（II）表示：在结构式（I） - （II）中，R 1和R 2独立地为脂族基团，取代的脂族基团，芳基或取代的芳基，或者R 1和R 2与它们所键合的碳原子和氮原子一起形成任选地与芳环稠合的非芳族杂环。当R 2为芳基或取代芳基时，R 5为肼保护基; 当R 2为脂肪族或取代的脂族基团时，R 5为-H或肼保护基。 R 10为-H或取代或未取代的烷基。该方法包括使起始化合物与亚硫酰化试剂反应的步骤。

8. 发明申请

US20060122183A1 Taxol enhancer compounds 有权
标题翻译：紫杉醇增强剂化合物
公开(公告)号：US20060122183A1
公开(公告)日：2006-06-08
申请号：US11244324
申请日：2005-10-05
申请人： Keizo Koya , Lijun Sun , Shoujun Chen , Noriaki Tatsuta , Yaming Wu , Mitsunori Ono
发明人： Keizo Koya , Lijun Sun , Shoujun Chen , Noriaki Tatsuta , Yaming Wu , Mitsunori Ono
IPC分类号： A61K31/53 , A61K31/505 , A61K31/44 , A61K31/337 , A61K31/277 , A61K31/16
CPC分类号： A61K47/48176 , A61K31/16 , A61K31/165 , A61K31/277 , A61K31/337 , A61K31/381 , A61K31/44 , A61K31/505 , A61K31/53 , A61K47/58 , C07C327/56 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D209/42 , C07D209/44 , C07D213/83 , C07D261/18 , C07D305/14 , C07D307/68 , C07D333/38 , C07D333/68 , C07D407/12
摘要： Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C=Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5—R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with taxol or an analog of taxol.
摘要翻译：公开了由结构式（I）表示的化合物：Y是共价键，亚苯基或取代或未取代的直链烃基。此外，Y与它所键合的两个> C = Z基团一起是取代或未取代的芳族基团。优选地，Y是共价键或-C（R 7 R 8） - 。 R 1和R 2分别独立地是芳基或取代的芳基，R 3和R 4是独立的-H，脂族基团，取代的脂族基团，芳基或取代的芳基。 R 5 -R 6独立地是-H，脂族基团，取代的脂族基团，芳基或取代的芳基。 R 7和R 8各自独立地为-H，脂族或取代的脂族基团或R 7为-H， 8是取代或未取代的芳基，或者R 7和R 8一起是C2-C6取代或未取代的亚烷基。 Z是-O或-S。还公开了包含本发明化合物和药学上可接受的载体或稀释剂的药物组合物。还公开了通过向受试者施用结构式（I）的化合物与紫杉醇或紫杉醇的类似物组合治疗患有癌症的受试者的方法。

9. 发明申请

US20050250770A1 Fused heterocyclic compounds 有权
标题翻译：稠合杂环化合物
公开(公告)号：US20050250770A1
公开(公告)日：2005-11-10
申请号：US10985627
申请日：2004-11-10
申请人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Teresa Przewloka , Hao Li , Zachary Demko , Dinesh Chimmanamada
发明人： Mitsunori Ono , Lijun Sun , Yumiko Wada , Teresa Przewloka , Hao Li , Zachary Demko , Dinesh Chimmanamada
IPC分类号： A61K31/517 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K31/541 , C07D239/84 , C07D239/88 , C07D239/94 , C07D239/95 , C07D401/12 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D409/04 , C07D413/14 , C07D471/04 , C07D475/06 , C07D491/04
CPC分类号： C07D239/95 , C04B35/632 , C07D215/40 , C07D239/84 , C07D239/94 , C07D401/12 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/04 , C07D409/04 , C07D413/14 , C07D471/04 , C07D475/06 , C07D491/04
摘要： This invention provides fused heterocyclic compounds, pharmaceutical compositions of, the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.
摘要翻译：本发明提供稠合杂环化合物，化合物的药物组合物和使用该化合物治疗特别是IL-12相关疾病和病症的方法。

10. 发明授权

US06800660B2 Taxol enhancer compounds 失效
标题翻译：紫杉醇增强剂化合物
公开(公告)号：US06800660B2
公开(公告)日：2004-10-05
申请号：US10193075
申请日：2002-07-10
申请人： Keizo Koya , Lijun Sun , Shoujun Chen , Noriaki Tatsuta , Yaming Wu , Mitsunori Ono
发明人： Keizo Koya , Lijun Sun , Shoujun Chen , Noriaki Tatsuta , Yaming Wu , Mitsunori Ono
IPC分类号： A61K3116
CPC分类号： A61K47/48176 , A61K31/16 , A61K31/165 , A61K31/277 , A61K31/337 , A61K31/381 , A61K31/44 , A61K31/505 , A61K31/53 , A61K47/58 , C07C327/56 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D209/42 , C07D209/44 , C07D213/83 , C07D261/18 , C07D305/14 , C07D307/68 , C07D333/38 , C07D333/68 , C07D407/12
摘要： Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C═Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ═O or ═S. Also disclosed are pharmaceutical compositions comprising the compound of the present invention and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject with cancer by administering to the subject a compound of Structural Formula (I) in combination with taxol or an analog of taxol.
摘要翻译：公开了由结构式（I）表示的化合物：Y是共价键，亚苯基或取代或未取代的直链烃基。此外，Y与它所键合的两个> C = Z基团一起是取代或未取代的芳族基团。优选地，Y是共价键或-C（R7R8） - ，R1和R2独立地是芳基或取代的芳基，R3和R4独立地是-H，脂族基团，取代的脂族基团，芳基或取代的芳基.R 5 -R 6独立地是-H，脂族基团，取代的脂族基团，芳基或取代的芳基.R 7和R 8各自独立地为-H，脂族或取代的脂族基团，或者R 7是 -H和R8是取代或未取代的芳基，或者R 7和R 8一起是C 2 -C 6取代或未取代的亚烷基。Z = O或= S。还公开了药物组合物，其包含本发明和药学上可接受的载体或稀释剂。还公开了通过向受试者施用结构式（I）的化合物与紫杉醇或紫杉醇的类似物组合治疗患有癌症的受试者的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式